Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Among those identified, 2.4 lakh patients have been notified from public health institutions, while 1.1 lakh were identified through private healthcare facilities
Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
AA Signature provides an innovative approach to treatment planning that focuses on patient outcomes
The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for metastatic breast cancer patients.
Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030
If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
In the US, the compassionate use approvals are provided by FDA in the form of individual patient-specific expanded-access IND
Subscribe To Our Newsletter & Stay Updated
